EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Multizentrische StudieOpen Access · CC BY-NC-ND 4.0

Metastatic sites of baseline as predictors in recurrent or metastatic nasopharyngeal carinoma treated with PD-L1 inhibitor: a secondary analysis of multicenter, single-arm, phase II study (KL-A167)

Yuantai Li, Yu Min, Zhigong Wei, Zheran Liu, Yiyan Pei, Yujie Yang, Kun Gao, Ge Song, Shihong Xu, Shuangshuang He, Junyou Ge, Yan Qing und 4 weitere

Cancer Immunology, Immunotherapy · 2025

DOI: 10.1007/s00262-024-03905-0 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Cancer Immunology, Immunotherapy, 2025. Verfasst von Yuantai Li und 15 weiteren Autor:innen. Beteiligte Einrichtung: Division of Head & Neck Tumor Multimodality Treatment, Department of Radiotherapy, Cancer Center, West China Hospital, Sichuan University, No. 37 Guo…. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, Nasopharyngeal Neoplasms, Neoplasm Recurrence, Local, B7-H1 Antigen. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immune Checkpoint InhibitorsNasopharyngeal NeoplasmsNeoplasm Recurrence, LocalB7-H1 AntigenHumansMaleMiddle AgedFemaleAdultNeoplasm MetastasisNasopharyngeal CarcinomaAgedPrognosis

Stichwörter der Autor:innen

Anti-PD-L1Metastatic sitesNasopharyngeal carcinomaSurvival

Substanzen

Immune Checkpoint InhibitorsB7-H1 AntigenCD274 protein, human

Autor:innen und Institutionen

  • Division of Head & Neck Tumor Multimodality Treatment, Department of Radiotherapy, Cancer Center, West China Hospital, Sichuan University, No. 37 Guo Xue Alley, Chengdu, Sichuan, China.
  • Department of Biotherapy, Cancer Center, West China Hospital, Sichuan University, No. 37 Guo Xue Alley, Sichuan, 610041, Chengdu, China.
  • Department of Intensive Care Medicine, Yan'an Affiliated Hospital of Kunming Medical University, Kunming, China.
  • Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Chengdu, Sichuan, China.
  • Division of Head & Neck Tumor Multimodality Treatment, Department of Radiotherapy, Cancer Center, West China Hospital, Sichuan University, No. 37 Guo Xue Alley, Chengdu, Sichuan, China. aiping00222@163.com.
  • Department of Abdominal Cancer, Cancer Center, West China Hospital, Sichuan University, No. 37 Guo Xue Alley, Sichuan, 610041, Chengdu, China. huaxichenye@163.com.

Zitieren

APA

Li, Y., Min, Y., Wei, Z., Liu, Z., Pei, Y., Yang, Y., Gao, K., Song, G., Xu, S., He, S., Ge, J., Qing, Y., Wei, Y., Ai, P., Chen, Y., & Peng, X. (2025). Metastatic sites of baseline as predictors in recurrent or metastatic nasopharyngeal carinoma treated with PD-L1 inhibitor: a secondary analysis of multicenter, single-arm, phase II study (KL-A167). Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-024-03905-0

Vancouver

Li Y, Min Y, Wei Z, Liu Z, Pei Y, Yang Y, et al. Metastatic sites of baseline as predictors in recurrent or metastatic nasopharyngeal carinoma treated with PD-L1 inhibitor: a secondary analysis of multicenter, single-arm, phase II study (KL-A167). Cancer Immunology, Immunotherapy. 2025. doi:10.1007/s00262-024-03905-0

BibTeX
@article{Li2025,
  author = {Li, Yuantai and Min, Yu and Wei, Zhigong and Liu, Zheran and Pei, Yiyan and Yang, Yujie and Gao, Kun and Song, Ge and Xu, Shihong and He, Shuangshuang and Ge, Junyou and Qing, Yan and Wei, Youneng and Ai, Ping and Chen, Ye and Peng, Xingchen},
  title = {Metastatic sites of baseline as predictors in recurrent or metastatic nasopharyngeal carinoma treated with PD-L1 inhibitor: a secondary analysis of multicenter, single-arm, phase II study (KL-A167)},
  journal = {Cancer Immunology, Immunotherapy},
  year = {2025},
  doi = {10.1007/s00262-024-03905-0}
}
Kostenlos starten →